Sen. John Boozman Sells Off Johnson & Johnson (NYSE:JNJ) Shares

Key Points

• Sen. John Boozman sold $1,001–$15,000 of Johnson & Johnson shares on August 20, according to a September 11 disclosure. He also sold shares of the iShares Core S&P 500 ETF while purchasing positions in Otis Worldwide, several small-cap and S&P 500 ETFs, and First Solar.
• Johnson & Johnson shares opened at $265.91, near their 52-week high, after the company beat quarterly earnings and revenue expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $274.13.
• J&J continues to offer a quarterly dividend of $1.34, or $5.36 annualized, yielding about 2%. New product approvals in China and Europe may support growth, although the stock’s valuation near 31 times earnings has prompted concerns that its rally could be losing momentum.

Senator John Boozman (Republican-Arkansas) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on September 11th, the Senator disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 20th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of iShares Core S&P 500 ETF NYSEARCA: IVV on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of Otis Worldwide NYSE: OTIS on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of State Street SPDR Portfolio S&P 500 ETF NYSEARCA: SPYM on 8/20/2026.
• Purchased $1,001 - $15,000 in shares of iShares Core S&P Small-Cap ETF NYSEARCA: IJR on 8/19/2026.
• Purchased $1,001 - $15,000 in shares of Avantis U.S. Small Cap Value ETF NYSEARCA: AVUV on 8/19/2026.
• Purchased $1,001 - $15,000 in shares of First Solar NASDAQ: FSLR on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Constellation Energy NASDAQ: CEG on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Cboe Global Markets BATS: CBOE on 7/31/2026.
• Purchased $1,001 - $15,000 in shares of PayPal NASDAQ: PYPL on 7/30/2026.
• Purchased $1,001 - $15,000 in shares of State Street SPDR Portfolio S&P 500 ETF NYSEARCA: SPYM on 7/23/2026.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $265.91 on Friday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $640.82 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The company's 50-day moving average price is $263.03 and its two-hundred day moving average price is $245.93.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the firm posted $2.77 EPS. The business's revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is 62.11%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Bullseye Investment Management LLC acquired a new stake in Johnson & Johnson during the second quarter worth $63,000. Talon Private Wealth LLC lifted its stake in Johnson & Johnson by 89.5% during the second quarter. Talon Private Wealth LLC now owns 10,588 shares of the company's stock worth $2,689,000 after purchasing an additional 5,002 shares during the period. U S Wealth Group LLC. lifted its stake in Johnson & Johnson by 15.1% during the second quarter. U S Wealth Group LLC. now owns 17,259 shares of the company's stock worth $4,383,000 after purchasing an additional 2,266 shares during the period. Miramontes Capital LLC boosted its holdings in Johnson & Johnson by 20.5% during the second quarter. Miramontes Capital LLC now owns 7,584 shares of the company's stock valued at $1,926,000 after purchasing an additional 1,289 shares in the last quarter. Finally, Core Capital Management & Research inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $1,087,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on JNJ shares. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Citigroup upped their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $274.13.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas' U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman's academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.